Nima Aghdam1, Michael Carrasquilla2, Edina Wang2, Abigail N Pepin2,3, Malika Danner2, Marilyn Ayoob2, Thomas Yung2, Brian T Collins2, Deepak Kumar4, Simeng Suy2, Sean P Collins2, Jonathan W Lischalk5. 1. Department of Radiation Medicine, Beth Israel Deaconess Medical Center, Boston, MA, United States. 2. Department of Radiation Medicine, MedStar Georgetown University Hospital, Washington, DC, United States. 3. George Washington University School of Medicine, Washington, DC, United States. 4. The Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, NC, United States. 5. Perlmutter Cancer Center, Langone Medical Center, New York University, New York, NY, United States.
Abstract
OBJECTIVES: Stereotactic Body Radiation Therapy (SBRT) offers definitive treatment for localized prostate cancer with comparable efficacy and toxicity to conventionally fractionated radiotherapy. Decreasing the number of treatment visits from over 40 to five may ease treatment burden and increase accessibility for logistically challenged patients. Travel distance is one factor that affects a patient's access to treatment and is often related to geographic location and socioeconomic status. In this study, we review the demographic and geographic factors of patients treated with SBRT for prostate cancer for a single institution with over a decade of experience. METHODS: Patient zip codes from one thousand and thirty-five patients were derived from a large, prospectively maintained quality of life database for patients treated for prostate cancer with SBRT from 2008 to 2017. The geospatial distance between the centroid of each zip code to our institution was calculated using the R package Geosphere. Characteristics for seven hundred and twenty-one patients were evaluated at the time of analysis including: race, age, and insurance status. To assess the geographic reach of our institution, we evaluated the demographic features of each zip code using US Census data. Statistical comparisons for these features and their relation to distance traveled for treatment was performed using the Mann-Whitney U test. Finally, an unsupervised learning algorithm was performed to identify distinct clusters of patients with respect to median income, racial makeup, educational level, and rural residency. RESULTS: Patients traveled from 246 distinct zip codes at a median distance of 11.35 miles. Forty percent of patients were African American, 6.9% resided in a rural region, and 22% were over the age of 75. Using K-means cluster analysis, four distinct patient zip-code groups were identified based on the aforementioned demographic features: Suburban/high-income (45%), Urban (30%), Suburban/low-income (17%), and Rural (8%). For each of the clusters, the average travel distance for SBRT was significantly different at 11.17, 9.26, 11.75, and 40.2 miles, respectively (p-value: <0.001). CONCLUSIONS: Distinct demographic features are related to travel distance for prostate SBRT. In our large cohort, travel distance did not prevent uptake of prostate SBRT in African American, elderly or rural patient populations. Prostate SBRT offers a diverse population modern treatment for their localized prostate cancer and particularly for those who live significant distances from a treatment center.
OBJECTIVES: Stereotactic Body Radiation Therapy (SBRT) offers definitive treatment for localized prostate cancer with comparable efficacy and toxicity to conventionally fractionated radiotherapy. Decreasing the number of treatment visits from over 40 to five may ease treatment burden and increase accessibility for logistically challenged patients. Travel distance is one factor that affects a patient's access to treatment and is often related to geographic location and socioeconomic status. In this study, we review the demographic and geographic factors of patients treated with SBRT for prostate cancer for a single institution with over a decade of experience. METHODS: Patient zip codes from one thousand and thirty-five patients were derived from a large, prospectively maintained quality of life database for patients treated for prostate cancer with SBRT from 2008 to 2017. The geospatial distance between the centroid of each zip code to our institution was calculated using the R package Geosphere. Characteristics for seven hundred and twenty-one patients were evaluated at the time of analysis including: race, age, and insurance status. To assess the geographic reach of our institution, we evaluated the demographic features of each zip code using US Census data. Statistical comparisons for these features and their relation to distance traveled for treatment was performed using the Mann-Whitney U test. Finally, an unsupervised learning algorithm was performed to identify distinct clusters of patients with respect to median income, racial makeup, educational level, and rural residency. RESULTS: Patients traveled from 246 distinct zip codes at a median distance of 11.35 miles. Forty percent of patients were African American, 6.9% resided in a rural region, and 22% were over the age of 75. Using K-means cluster analysis, four distinct patient zip-code groups were identified based on the aforementioned demographic features: Suburban/high-income (45%), Urban (30%), Suburban/low-income (17%), and Rural (8%). For each of the clusters, the average travel distance for SBRT was significantly different at 11.17, 9.26, 11.75, and 40.2 miles, respectively (p-value: <0.001). CONCLUSIONS: Distinct demographic features are related to travel distance for prostate SBRT. In our large cohort, travel distance did not prevent uptake of prostate SBRT in African American, elderly or rural patient populations. Prostate SBRT offers a diverse population modern treatment for their localized prostate cancer and particularly for those who live significant distances from a treatment center.
Authors: Tracy Onega; Eric J Duell; Xun Shi; Eugene Demidenko; Daniel Gottlieb; David C Goodman Journal: Med Care Res Rev Date: 2009-05-19 Impact factor: 3.929
Authors: Joseph C Hodges; Yair Lotan; Thomas P Boike; Rhonda Benton; Alyson Barrier; Robert D Timmerman Journal: J Oncol Pract Date: 2012-05 Impact factor: 3.840
Authors: Shaan Kataria; Harsha Koneru; Shan Guleria; Malika Danner; Marilyn Ayoob; Thomas Yung; Siyuan Lei; Brian T Collins; Simeng Suy; John H Lynch; Thomas Kole; Sean P Collins Journal: Front Oncol Date: 2017-07-24 Impact factor: 6.244
Authors: Tamir N Sholklapper; Michael L Creswell; Alexandra T Payne; Michael Markel; Abigail Pepin; Michael Carrasquilla; Alan Zwart; Malika Danner; Marilyn Ayoob; Thomas Yung; Brian Collins; Deepak Kumar; Nima Aghdam; Simeng Suy; Ryan A Hankins; Keith Kowalczyk; Sean P Collins Journal: Front Oncol Date: 2022-03-25 Impact factor: 6.244